February 17, 2022
A New York bankruptcy judge Thursday gave Purdue Pharma a two-week extension on an injunction pausing litigation against the company after being told the drugmaker is closing in on an agreement for a new Chapter 11 plan.
February 09, 2022
A New York federal judge on Wednesday approved a belated appeal filed by Canadian entities challenging Purdue Pharma's Chapter 11 plan, hours after Purdue said it had no problem with the appeal going forward before the Second Circuit.
February 08, 2022
Canadian entities are seeking permission to file a late appeal to a New York federal court ruling that vacated Purdue Pharma's Chapter 11 plan, saying Tuesday there are unresolved issues related to their claims that won't be covered by the drugmaker's challenge in the Second Circuit.
February 04, 2022
Purdue Pharma has asked a New York bankruptcy judge for another extension on the opioid litigation injunction that has been in place since it filed for bankruptcy, citing word that a settlement agreement is near on a modified reorganization plan and the considerable work that would follow.
February 01, 2022
A New York bankruptcy judge extended a mediation deadline Tuesday in the Chapter 11 case of Purdue Pharma after the mediator reported the parties were close to a deal that would see members of the Sackler family significantly increase their more than $4.3 billion in payments under the debtor's scuttled plan.
January 03, 2022
Health care and life sciences litigation is already red hot as 2022 begins and appears all but certain to intensify throughout the year as the clock ticks on time-sensitive lawsuits, the U.S. Supreme Court nears the end of its current term and opioid cases generate more trials and fresh drama. Here, Law360 explores five key litigation areas to watch.
December 06, 2021
Members of the Sackler family who own drugmaker Purdue Pharma told a New York federal judge Monday that they did not increase transfers of cash out of the business in the run-up to its 2019 Chapter 11 filing, and instead left the company with more unrestricted cash than ever before at that time.
November 18, 2021
A New York bankruptcy judge approved a request from drugmaker Purdue Pharma LP to reimburse more than $12 million in fees incurred by groups representing government entities in its Chapter 11 plan mediation process, saying the groups made significant contributions to the confirmed plan.
November 09, 2021
A New York bankruptcy judge said Tuesday that a stay of the implementation of Purdue Pharma's Chapter 11 plan pending appeals was unnecessary after Purdue agreed not to take the plan's final steps until after the first round of appeals are decided.
October 25, 2021
Purdue Pharma LP is arguing that delaying the consummation of its Chapter 11 plan to allow appeals to be resolved first would needlessly delay the distribution of billions of dollars for opioid abatement efforts while there was no danger of prejudice to the appellants.